Cover Image
市場調查報告書

失眠症:開發中產品分析

Insomnia - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232809
出版日期 內容資訊 英文 101 Pages
訂單完成後即時交付
價格
Back to Top
失眠症:開發中產品分析 Insomnia - Pipeline Review, H2 2016
出版日期: 2016年11月09日 內容資訊: 英文 101 Pages
簡介

本報告提供失眠症治療藥的開發趨勢調查,提供您各臨床實驗階段的產品概要,主要企業藥物簡介,開發中產品的最新趨勢等資訊。

簡介

  • 調查範圍

失眠症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

失眠症:企業開發中的治療藥

失眠症:大學/機關研究中的治療藥

失眠症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 失眠症:企業開發中的產品
  • 失眠症:大學/機關研究中的產品
  • 失眠症的治療藥開發企業
  • Eisai
  • Evotec AG
  • Grupo Ferrer Internacional, S.A.
  • Heptares Therapeutics Limited
  • Intec Pharma ltd.
  • Intra-Cellular Therapies, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Neurim Pharmaceuticals Ltd
  • Novartis AG
  • Reviva Pharmaceuticals Inc.
  • 鹽野義製藥
  • 武田藥品工業

失眠症:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

失眠症:最近的開發平台趨勢

失眠症:暫停中的計劃

失眠症:開發中止的產品

失眠症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8636IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Insomnia - Pipeline Review, H2 2016, provides an overview of the Insomnia (Central Nervous System) pipeline landscape.

Insomnia is a sleep disorder that is characterized by difficulty falling and/or staying asleep. Symptoms include difficulty falling asleep at night, irritability, depression or anxiety, tension headaches and distress in the stomach and intestines. Risk factors include age, mental health disorder, stress and shift working.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Insomnia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Insomnia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Insomnia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Insomnia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 9, 3, 6 and 3 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 3 molecules, respectively.Insomnia.

Insomnia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Insomnia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Insomnia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Insomnia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Insomnia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Insomnia (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Insomnia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Insomnia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Insomnia Overview
  • Therapeutics Development
    • Pipeline Products for Insomnia - Overview
    • Pipeline Products for Insomnia - Comparative Analysis
  • Insomnia - Therapeutics under Development by Companies
  • Insomnia - Therapeutics under Investigation by Universities/Institutes
  • Insomnia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Insomnia - Products under Development by Companies
  • Insomnia - Products under Investigation by Universities/Institutes
  • Insomnia - Companies Involved in Therapeutics Development
    • Actelion Ltd
    • Alexza Pharmaceuticals, Inc.
    • Eisai Co., Ltd.
    • Evotec AG
    • Grupo Ferrer Internacional, S.A.
    • Heptares Therapeutics Limited
    • Intec Pharma Ltd
    • Intra-Cellular Therapies, Inc.
    • Johnson & Johnson
    • Leading BioSciences, Inc.
    • Merck & Co., Inc.
    • Neurim Pharmaceuticals Ltd
    • Novartis AG
    • Reviva Pharmaceuticals Inc.
    • Shionogi & Co., Ltd.
    • Takeda Pharmaceutical Company Limited
  • Insomnia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (diphenhydramine + lorazepam + zolpidem tartrate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACT-541468 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CB-2810 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DORA-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug for Insomnia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Inhibit Angiotensin II Receptor Type 1 for Insomnia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EVT-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HTL-6641 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ITI-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-42847922 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-48816274 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LASSBio-785 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LASSBio-786 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lemborexant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lorediplon - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MK-8133 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NEO-1940 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • piromelatine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ramelteon - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-117957 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Insomnia, Obesity and Treatment Resistant Depression - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize Orexin Receptor Type 1 and 2 for Insomnia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit OX2R for Insomnia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate CYP1A2 for Insomnia and Anxiety - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • UCM-765 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • zaleplon - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • zaleplon - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • zolpidem tartrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Insomnia - Dormant Projects
  • Insomnia - Discontinued Products
  • Insomnia - Product Development Milestones
    • Featured News & Press Releases
      • Sep 08, 2016: Ergomed Completes Recruitment of Phase IIa Clinical Trial of Lorediplon in Insomnia in Collaboration with co-development Partner Ferrer
      • Jul 07, 2016: Actelion To Enter Phase II Clinical Development With New Dual Orexin Receptor Antagonist In Patients With Insomnia
      • Jun 01, 2016: Minerva Neurosciences to Present data on MIN-202
      • Feb 01, 2016: Minerva Neurosciences Announces Top Line Data From MIN-202 Phase I Clinical Study in Japanese Patients
      • Jan 11, 2016: Minerva Neurosciences Announces Favorable Top Line Results From MIN-202 Phase 2A Clinical Trial in Insomnia Disorder
      • Dec 16, 2015: Intec Pharma Further Expands Intellectual Property with a New Patent for the Accordion Pill Zaleplon in Europe
      • Dec 09, 2015: Minerva Provides Year-End Update on Clinical Trial With Central Nervous System Product Candidate MIN-202
      • Sep 24, 2015: Minerva Neurosciences Provides Update on Clinical Development Program With MIN-202, Selective Orexin-2 Receptor Antagonist
      • Jul 14, 2015: Ferrer initiates phase IIa clinical study of Lorediplon in patients with insomnia
      • Jun 16, 2015: Minerva Neurosciences Provides Update on MIN-202, Selective Orexin-2 Receptor Antagonist
      • Jan 21, 2015: Minerva Neurosciences Reports Positive Phase 1 Data With MIN-202, Selective Orexin-2 Antagonist for Treatment of Sleep Disorders Including Primary and Comorbid Insomnia
      • Dec 10, 2014: Eisai Demonstrates Efficacy Of Investigational Dual Orexin Receptor Antagonist E2006 In Sleep Initiation And Maintenance
      • Sep 22, 2014: Minerva Neurosciences Announces Completion of FDA Review of Investigational New Drug Application for MIN-202 and Plans for First U.S.-Based Clinical Trial
      • Jul 26, 2013: Takeda Pharma Receives FDA Approval For Rozerem
      • Feb 18, 2013: Neurim Pharma Announces Positive Phase II Clinical Trial Results Of Piromelatine For Treatment Of Insomnia
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Insomnia, H2 2016
  • Number of Products under Development for Insomnia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Insomnia - Pipeline by Actelion Ltd, H2 2016
  • Insomnia - Pipeline by Alexza Pharmaceuticals, Inc., H2 2016
  • Insomnia - Pipeline by Eisai Co., Ltd., H2 2016
  • Insomnia - Pipeline by Evotec AG, H2 2016
  • Insomnia - Pipeline by Grupo Ferrer Internacional, S.A., H2 2016
  • Insomnia - Pipeline by Heptares Therapeutics Limited, H2 2016
  • Insomnia - Pipeline by Intec Pharma Ltd, H2 2016
  • Insomnia - Pipeline by Intra-Cellular Therapies, Inc., H2 2016
  • Insomnia - Pipeline by Johnson & Johnson, H2 2016
  • Insomnia - Pipeline by Leading BioSciences, Inc., H2 2016
  • Insomnia - Pipeline by Merck & Co., Inc., H2 2016
  • Insomnia - Pipeline by Neurim Pharmaceuticals Ltd, H2 2016
  • Insomnia - Pipeline by Novartis AG, H2 2016
  • Insomnia - Pipeline by Reviva Pharmaceuticals Inc., H2 2016
  • Insomnia - Pipeline by Shionogi & Co., Ltd., H2 2016
  • Insomnia - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Insomnia - Dormant Projects, H2 2016
  • Insomnia - Dormant Projects (Contd..1), H2 2016
  • Insomnia - Dormant Projects (Contd..2), H2 2016
  • Insomnia - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Insomnia, H2 2016
  • Number of Products under Development for Insomnia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top